C. Gong

发表

Heterogeneity derived from 18F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients

Shaoli Song, Xichun Hu, Biyun Wang, 2022, Cancer medicine.

Pretreatment F‐FDG Uptake Heterogeneity Predicts Treatment Outcome of First‐Line Chemotherapy in Patients with Metastatic Triple‐Negative Breast Cancer

Zhonghua Wang, Yizhao Xie, Yannan Zhao, 2018 .

Pretreatment 18 F ‐ FDG Uptake Heterogeneity Predicts Treatment Outcome of First ‐ Line Chemotherapy in Patients with Metastatic Triple ‐ Negative Breast Cancer

Zhonghua Wang, Yizhao Xie, Yannan Zhao, 2018 .

Jian Zhang, Leiping Wang, Xichun Hu, 2021 .

Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer.

Ting Li, Jian Zhang, Leiping Wang, 2021, Annals of palliative medicine.

MicroRNA-320 a inhibits proliferation and invasion of breast cancer cells by targeting RAB 11 A

Hong Wang, Lijie Ma, Xichun Hu, 2015 .

TCRM_A_255365 607..615

Jian Zhang, Leiping Wang, Xichun Hu, 2020 .

18 F-FES PET/CT In ﬂ uences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18 F-FDG PET/CT

C. Gong, Shuai Liu, Zhongyi YANGa, 2019 .

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET

Shaoli Song, Xichun Hu, Biyun Wang, 2022, Cancers.

MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A.

Hong Wang, Lijie Ma, Xichun Hu, 2015, American journal of cancer research.

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

Jian Zhang, Leiping Wang, Xichun Hu, 2022, Cancers.

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data

Jian Zhang, Leiping Wang, Xichun Hu, 2022, Therapeutic advances in drug safety.

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

Jian Zhang, Zhonghua Wang, Xichun Hu, 2017, Oncotarget.

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

S. Zhang, Jian Zhang, Zhonghua Wang, 2017, Oncotarget.

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method

YingJian Zhang, Jian Zhang, Zhonghua Wang, 2019, Cancer management and research.

Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients

Ting Li, Jian Zhang, Leiping Wang, 2020, Frontiers in Oncology.

A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel

Jian Zhang, Leiping Wang, Biyun Wang, 2017, Scientific Reports.

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

P. Yuan, Jian Zhang, Leiping Wang, 2019, Scientific Reports.

18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT.

C. Liu, Biyun Wang, Cheng Liu, 2019, The oncologist.

A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2− metastatic breast cancer

Wei Li, Biyun Wang, C. Gong, 2021, Therapeutic advances in medical oncology.

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer

Jian Zhang, Leiping Wang, Xichun Hu, 2020, Cancer medicine.

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience

S. Zhang, Jian Zhang, Leiping Wang, 2020, Therapeutics and clinical risk management.

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study

Wei Li, Biyun Wang, T. Luo, 2020, Frontiers in Oncology.

The diversity of the intestinal microbiota in patients with alcohol use disorder and its relationship to alcohol consumption and cognition

Lin Li, C. Gong, Yishan Du, 2022, Frontiers in Psychiatry.

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

Ting Li, Jian Zhang, Leiping Wang, 2021, BMC Cancer.

Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

YingJian Zhang, Guang Ma, Jian Zhang, 2018, The oncologist.

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer

S. Zhang, Ting Li, Jian Zhang, 2017, Oncotarget.

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study

Wei Li, Jian Zhang, Biyun Wang, 2021, Therapeutic advances in medical oncology.

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer

Jian Zhang, Leiping Wang, Xichun Hu, 2019, Scientific Reports.

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer

Shaoli Song, YingJian Zhang, Bi-bo Wang, 2021, International journal of general medicine.

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

YingJian Zhang, Biyun Wang, Yizhao Xie, 2018, Scientific Reports.

Yajia Gu, Qin Xiao, Jian Zhang, 2020, The oncologist.

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

YingJian Zhang, Biyun Wang, Yizhao Xie, 2018, Scientific Reports.

Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study

Xin Liu, C. Gong, Chunmeng Wang, 2023, Cancer research and treatment.

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer

Biyun Wang, Yizhao Xie, Yannan Zhao, 2023, Frontiers in endocrinology.

Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.

Wei Li, X. Guan, Jian Zhang, 2019, Clinical breast cancer.

Heterogeneity of targeted lung lesion predicts platinum-based ﬁ rst-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “ PET biopsy ” method

Xichun Hu, Biyun Wang, Yannan Zhao, 2019 .